News Sentiment

SLS sentiment intelligence

Sellas Life Sciences Group Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.19 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+3.4% over one week, +63.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

SELLAS Life Sciences Group Stock Short Interest Falls to 32.33%

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 3.4% Price confirming higher
Trend fit Trend active 63.9% over four weeks
Fair value 472.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 23
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
simplywall.st 8
TradingView 6
StocksToTrade 4
Stocktwits 3
Moomoo 3
Quiver Quantitative 2
TechStock² 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 17
Analyst action 4
Deals and strategy 4
Balance sheet 3
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Market source Direct company coverage

SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War

Shares of Sellas Life Sciences (SLS) increased following speculation among retail traders that the final acute myeloid leukemia (AML) readout, coupled with CEO Angelos Stergiou's upcoming Fox appearance, could attract Big Pharma interest. The company's Phase 3 Regal trial for gal

Tone
Positive 72/100
Event
Market update
Published
20 Jul 2026 02:39
Source
Market source
Stocktwits Direct company coverage

SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints

Sellas Life Sciences (SLS) stock is experiencing a significant surge as the company approaches a critical Phase 3 AML study readout and prepares for several investor conferences. The Phase 3 Regal study for acute myeloid leukemia is just two events away from final analysis, and t

Tone
Positive 94/100
Event
Market update
Published
19 Jul 2026 08:09
Source
Stocktwits
TechStock² Direct company coverage

SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results

SELLAS Life Sciences Group (NASDAQ:SLS) saw a 12.3% surge on Friday, reaching $13.19, which highlighted a significant $319 million discrepancy in its market capitalization calculations. This deficit arises from differing share counts used for valuation (weighted average vs. repor

Tone
Neutral 50/100
Event
Earnings
Published
18 Jul 2026 14:39
Source
TechStock²
TechStock² Direct company coverage

SELLAS Life Sciences (NASDAQ:SLS) Shares Climb 12% as Estimated Equity Value Rises $1.6 Billion Since May

SELLAS Life Sciences (NASDAQ:SLS) saw its shares climb 12.3% on Friday, reaching $13.19, contributing to a $1.62 billion increase in its estimated equity value since May. This rebound follows earlier drops in the week, with the equity value now standing at approximately $2.59 bil

Tone
Positive 76/100
Event
Market update
Published
17 Jul 2026 22:10
Source
TechStock²
Market source Direct company coverage

Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result

Sellas Life Sciences (SLS) stock rose 12% following anticipation of key clinical trial results for its Galinpepimut-S (GPS) treatment for acute myeloid leukemia, which is nearing its pre-specified patient death threshold. Investor enthusiasm is also fueled by speculation of a pot

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 20:10
Source
Market source
Quiver Quantitative Direct company coverage

Why SELLAS Life Sciences Group (SLS) Stock Is Up Today

SELLAS Life Sciences Group (SLS) stock is up 10.5% today, likely driven by anticipation of results from its pivotal Phase 3 REGAL trial in acute myeloid leukemia, with 78 of 80 required events already occurred. The company's strong liquidity and recent bullish analyst target incr

Tone
Positive 71/100
Event
Analyst action
Published
17 Jul 2026 18:37
Source
Quiver Quantitative
StocksToTrade Direct company coverage

SLS Stock Pops As Price Target Jumps On REGAL Trial Hopes

SELLAS Life Sciences Group Inc. (SLS) stock has seen a significant price target increase from Alliance Global, jumping from $10 to $25 with a reaffirmed Buy rating. This bullish sentiment is largely driven by optimism surrounding the Phase 3 REGAL trial for Galinpepimut-S in acut

Tone
Positive 77/100
Event
Analyst action
Published
17 Jul 2026 18:10
Source
StocksToTrade
timothysykes.com Direct company coverage

SLS Stock Climbs As Analyst Upside Targets REGAL Trial

SELLAS Life Sciences Group Inc. (SLS) stock rose over 10% following Alliance Global raising its price target to $25 from $10, driven by optimism around the Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia. The extended timeline for the trial's required deaths is i

Tone
Positive 74/100
Event
Analyst action
Published
17 Jul 2026 11:32
Source
timothysykes.com
TradingView Direct company coverage

SLS Stock Jumps Overnight After New Investor Disclosure – Retail Flags ‘Massive’ Options Bet Ahead Of AML Data

Sellas Life Sciences (SLS) stock saw a 1% overnight increase, driven by a new institutional investment from Armstrong Advisory Group, which reported a new position of 380 shares. This rise also follows attention from retail traders who have flagged significant call options activi

Tone
Positive 82/100
Event
Market update
Published
14 Jul 2026 22:41
Source
TradingView
Moomoo Direct company coverage

Why SELLAS Life Sciences Group (SLS) Stock Is Down Today

This article explains why SELLAS Life Sciences Group (SLS) stock has experienced a decline today. It delves into the specific factors and news that have negatively impacted the company's stock performance.

Tone
Negative 13/100
Event
Market update
Published
09 Jul 2026 05:48
Source
Moomoo
Stocktwits Direct company coverage

SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success

Shares of Sellas Life Sciences (SLS) experienced their worst day in over a month, sliding 10% to $13.27, despite a clinical-trials prediction market indicating an 83% probability of success for their GPS therapy in acute myeloid leukemia (AML). The prediction market projects Nove

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 00:09
Source
Stocktwits
StocksToTrade Direct company coverage

SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals

SELLAS Life Sciences Group Inc. (SLS) stock has experienced significant volatility, trading down 9.11% after a surge fueled by WallStreetBets social media buzz. Despite recent gains of 18% and 7% premarket without fundamental company news, the stock's price action is driven by sp

Tone
Negative 31/100
Event
Market update
Published
08 Jul 2026 17:40
Source
StocksToTrade
Benzinga Direct company coverage

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall

SELLAS Life Sciences (SLS) shares experienced volatility and slipped on Wednesday, trading lower as the stock encountered a $16 resistance level. Despite the recent dip, the company maintains a bullish outlook, with its stock trading significantly above major moving averages. Thi

Tone
Negative 42/100
Event
Guidance
Published
08 Jul 2026 14:40
Source
Benzinga
Intellectia AI Direct company coverage

Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment

Sellas Life Sciences (SLS) is experiencing strong retail investor interest, with 50% of 3,400 polled users favoring the stock, driven by the nearing completion of its Phase 3 Regal trial for acute myeloid leukemia. Speculation around potential acquisitions, fueled by optimistic r

Tone
Positive 87/100
Event
Deals and strategy
Published
07 Jul 2026 08:39
Source
Intellectia AI
Moomoo Direct company coverage

Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth

This article analyzes SELLAS Life Sciences Group's financial position, specifically its cash reserves and burn rate. It concludes that despite having substantial cash, the company's high burn rate means it can only fund current operations for a little over a year without seeking

Tone
Negative 37/100
Event
Balance sheet
Published
06 Jul 2026 13:10
Source
Moomoo
Intellectia AI Direct company coverage

SLS Should I Buy

This article analyzes Sellas Life Sciences Group Inc (SLS) and recommends it as a speculative buy for long-term investors, citing a bullish technical trend, accelerating insider buying, and positive news regarding clinical trial progress. Despite missing financial data and high e

Tone
Positive 77/100
Event
Market update
Published
03 Jul 2026 08:39
Source
Intellectia AI
Finviz Direct company coverage

SLS - SELLAS Life Sciences Group Inc Options

This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional

Tone
Positive 61/100
Event
Earnings
Published
02 Jul 2026 18:39
Source
Finviz
Sahm Direct company coverage

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

SELLAS Life Sciences (NASDAQ: SLS) shares dropped on Tuesday due to early profit-taking following a recent breakout. The stock's previous surge was fueled by an 8-K filing detailing executive employment agreements and anticipation for Phase 3 REGAL trial results for galinpepimut

Tone
Negative 39/100
Event
Earnings
Published
02 Jul 2026 07:40
Source
Sahm
TradingView Direct company coverage

Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today?

Shares of Sellas Life Sciences Group Inc. (SLS), BlackBerry Ltd. (BB), and Ouster Inc. (OUST) reached 52-week highs on Monday due to positive catalysts and optimistic growth outlooks. SLS surged anticipating Phase 3 trial results for its AML immunotherapy, BB rose after strong ea

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 19:09
Source
TradingView